Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy.
Humans
Female
Drug Resistant Epilepsy
/ blood
Male
Adult
Encephalitis
/ blood
Middle Aged
Diagnosis, Differential
Young Adult
Autoantibodies
/ blood
Hashimoto Disease
/ blood
Metabolomics
Nerve Tissue Proteins
/ blood
Adolescent
Membrane Proteins
/ blood
Magnetic Resonance Spectroscopy
Intracellular Signaling Peptides and Proteins
/ blood
Biomarkers
/ blood
Receptors, N-Methyl-D-Aspartate
/ immunology
Autoimmune Diseases of the Nervous System
/ blood
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
24
04
2024
received:
12
01
2024
accepted:
17
05
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
ppublish
Résumé
Differentiating forms of autoimmune encephalitis (AE) from other causes of seizures helps expedite immunotherapies in AE patients and informs studies regarding their contrasting pathophysiology. We aimed to investigate whether and how Nuclear Magnetic Resonance (NMR)-based metabolomics could differentiate AE from drug-resistant epilepsy (DRE), and stratify AE subtypes. This study recruited 238 patients: 162 with DRE and 76 AE, including 27 with contactin-associated protein-like 2 (CASPR2), 29 with leucine-rich glioma inactivated 1 (LGI1) and 20 with N-methyl-d-aspartate receptor (NMDAR) antibodies. Plasma samples across the groups were analyzed using NMR spectroscopy and compared with multivariate statistical techniques, such as orthogonal partial least squares discriminant analysis (OPLS-DA). The OPLS-DA model successfully distinguished AE from DRE patients with a high predictive accuracy of 87.0 ± 3.1% (87.9 ± 3.4% sensitivity and 86.3 ± 3.6% specificity). Further, pairwise OPLS-DA models were able to stratify the three AE subtypes. Plasma metabolomic signatures of AE included decreased high-density lipoprotein (HDL, -(CH This study presents the first non-antibody-based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.
Substances chimiques
LGI1 protein, human
0
CNTNAP2 protein, human
0
Autoantibodies
0
Nerve Tissue Proteins
0
Membrane Proteins
0
Intracellular Signaling Peptides and Proteins
0
Biomarkers
0
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1897-1908Subventions
Organisme : NIHR Oxford Biomedical Research Centre
Organisme : Epilepsy Research UK
Organisme : UCB Pharma
Organisme : National Medical Research Council
ID : MOH-TA20nov-002
Organisme : Dorothy Hodgkin Early Career Fellowship in Chemistry
Organisme : MRF
ID : MR/V007173/1
Pays : United Kingdom
Organisme : Wellcome Trust Fellowship
ID : 104079/Z/14/Z
Organisme : the Fulbright UK-US Commission
Organisme : British Medical Association
Organisme : Irish Clinical Academic Training Programme
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
World Health Organization. Epilepsy: A Public Health Imperative. World Health Organization; 2019 [cited 2023 Aug 16]. Available from: https://apps.who.int/iris/handle/10665/325293
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life‐time epilepsy: a meta‐analytic approach. Epilepsia. 2010;51(5):883‐890.
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839‐887.
Ramanathan S, Al‐Diwani A, Waters P, Irani SR. The autoantibody‐mediated encephalitides: from clinical observations to molecular pathogenesis. J Neurol. 2021;268(5):1689‐1707.
Sun B, Ramberger M, O'Connor KC, et al. The B cell immunobiology that underlies CNS autoantibody‐mediated diseases. Nat Rev Neurol. 2020;16(9):481‐492.
Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain J Neurol. 2018;141(2):348‐356.
Flanagan EP, Geschwind MD, Lopez‐Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30‐39.
Van Steenhoven RW, de Vries JM, Bruijstens AL, et al. Mimics of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200148.
Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune‐associated epilepsy: conceptual definitions. Epilepsia. 2020;61(7):1341‐1351.
Smith KM, Dubey D, Liebo GB, Flanagan EP, Britton JW. Clinical course and features of seizures associated with LGI1‐antibody encephalitis. Neurology. 2021;97(11):e1141‐e1149.
Nosadini M, Eyre M, Molteni E, et al. Use and safety of immunotherapeutic management of N‐methyl‐d‐aspartate receptor antibody encephalitis: a meta‐analysis. JAMA Neurol. 2021;78(11):1333‐1344.
Dalmau J, Graus F. Antibody‐mediated encephalitis. N Engl J Med. 2018;378(9):840‐851.
Lee SK, Lee S‐T. The laboratory diagnosis of autoimmune encephalitis. J Epilepsy Res. 2016;6(2):45‐52.
Nagana Gowda GA, Raftery D. Biomarker discovery and translation in metabolomics. Curr Metabolomics. 2013;1(3):227‐240.
Jurynczyk M, Probert F, Yeo T, et al. Metabolomics reveals distinct, antibody‐independent, molecular signatures of MS, AQP4‐antibody and MOG‐antibody disease. Acta Neuropathol Commun. 2017;5(1):95.
Lennox B, Xiong W, Waters P, et al. The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis. Mol Psychiatry. 2022;1–9:4722‐4730.
Irani SR, Bera K, Waters P, et al. N‐methyl‐d‐aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non‐paraneoplastic disorder of both sexes. Brain. 2010;133(6):1655‐1667.
Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel‐complex proteins leucine‐rich, glioma inactivated 1 protein and contactin‐associated protein‐2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734‐2748.
Soininen P, Kangas AJ, Würtz P, et al. High‐throughput serum NMR metabonomics for cost‐effective holistic studies on systemic metabolism. Analyst. 2009;134(9):1781‐1785.
Tynkkynen T, Mursu J, Nurmi T, Tuppurainen K, Laatikainen R, Soininen P. NMR protocol for determination of oxidation susceptibility of serum lipids and application of the protocol to a chocolate study. Metabolomics. 2012;8(3):386‐398.
Oostendorp M, Engelke UFH, Willemsen MAAP, Wevers RA. Diagnosing inborn errors of lipid metabolism with proton nuclear magnetic resonance spectroscopy. Clin Chem. 2006;52(7):1395‐1405.
Nicholson JK, Foxall PJ, Spraul M, et al. 750 MHz 1H and 1H–13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67(5):793‐811.
Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35:D521‐D526.
Thévenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J Proteome Res. 2015;14(8):3322‐3335.
Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49(W1):W388‐W396.
Woodhall M, Mgbachi V, Fox H, Irani S, Waters P. Utility of live cell‐based assays for autoimmune neurology diagnostics. J Appl Lab Med. 2022;7(1):391‐393.
McCracken L, Zhang J, Greene M, et al. Improving the antibody‐based evaluation of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e404.
Zhang F, Gao X, Liu J, Zhang C. Biomarkers in autoimmune diseases of the central nervous system. Front Immunol. 2023;14:1111719.
Wesselingh R, Griffith S, Broadley J, et al. Peripheral monocytes and soluble biomarkers in autoimmune encephalitis. J Autoimmun. 2023;135:103000.
Levraut M, Bourg V, Capet N, et al. Cerebrospinal fluid IL‐17A could predict acute disease severity in non‐NMDA‐receptor autoimmune encephalitis. Front Immunol. 2021;12:673021.
Brenner J, Mariotto S, Bastiaansen AEM, et al. Predictive value of serum neurofilament light chain levels in anti‐NMDA receptor encephalitis. Neurology. 2023;100(21):e2204‐e2213.
Anderyas P, Halliday A, Reardon K. Anti‐LGI1‐associated myopathy in the setting of neuromuscular hyperexcitability syndrome. JAMA Neurol. 2022;79(12):1319‐1320.
Wu K, Wen L, Duan R, et al. Triglyceride level is an independent risk factor in first‐attacked neuromyelitis optica spectrum disorders patients. Front Neurol. 2019;10:1230.
Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler. 2014;20(13):1737‐1744.
Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. J Neurol Neurosurg Psychiatry. 2017;88(5):395‐401.
Cho EB, Cho H‐J, Choi M, et al. Low high‐density lipoprotein cholesterol and high triglycerides lipid profile in neuromyelitis optica spectrum disorder: associations with disease activity and disability. Mult Scler Relat Disord. 2020;40:101981.
Liu F, Wang B, Wang C, Zhang B, Guo S. Lipid profiles and their potential inflammatory effects in anti‐N‐methyl‐d‐aspartate receptor encephalitis. Neurol Sci. 2021;42(7):2881‐2890.
Shu Y, Qin B, Xu Y, et al. Lipid metabolism in patients with anti‐N‐methyl‐d‐aspartate receptor encephalitis. Neuroimmunomodulation. 2017;24(4–5):256‐263.
Liu F, Huang T, Wang B, Wang C, Guo S. Low high‐density lipoprotein cholesterol and apolipoprotein A‐I levels are associated with poor outcome and relapse in autoimmune encephalitis. Neurosci Lett. 2022;775:136546.
Campos AM, Maciel E, Moreira ASP, et al. Lipidomics of mesenchymal stromal cells: understanding the adaptation of phospholipid profile in response to pro‐inflammatory cytokines. J Cell Physiol. 2016;231(5):1024‐1032.
Shu Y, Xu Y, Chen C, et al. Serum bilirubin and albumin in anti‐N‐methyl‐d‐aspartate receptor encephalitis. Neuroimmunomodulation. 2018;25(4):206‐214.
Jang Y, Lee S‐T, Kim T‐J, et al. High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis. Sci Rep. 2018;8(1):1012.
Lyons O, Whelan B, Bennett K, O'Riordan D, Silke B. Serum albumin as an outcome predictor in hospital emergency medical admissions. Eur J Intern Med. 2010;21(1):17‐20.
Ishida S, Hashimoto I, Seike T, et al. Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. J Med Invest. 2014;61(3‐4):361‐368.
Manosalva C, Quiroga J, Hidalgo AI, et al. Role of lactate in inflammatory processes: friend or foe. Front Immunol. 2022;12:808799. doi:10.3389/fimmu.2021.808799
Amorini AM, Nociti V, Petzold A, et al. Serum lactate as a novel potential biomarker in multiple sclerosis. Biochim Biophys Acta. 2014;1842(7):1137‐1143.
Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81‐151.
Mallagaray A, Rudolph L, Lindloge M, et al. Towards a precise NMR quantification of acute phase inflammation proteins from human serum. Angew Chem Int ed. 2023;62(35):e202306154.
Ormseth MJ, Chung CP, Oeser AM, et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther. 2015;17(1):117.
Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein parameters in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43(4):745‐750.
Hanin A, Chollet C, Demeret S, di Meglio L, Castelli F, Navarro V. Metabolomic changes in adults with status epilepticus: a human case‐control study. Epilepsia. 2024;65:929‐943.